NorthStar, IBA expand Tc-99m collaboration

By staff writers

March 8, 2021 -- NorthStar Medical Radioisotopes and proton therapy developer Ion Beam Applications (IBA) are expanding their collaboration in an effort to increase the supply of technetium-99m (Tc-99m) around the world.

Under the new partnership, companies outside the U.S. will now be able to purchase Tc-99m generation systems that utilize NorthStar's nonuranium-based molybdenum-99 (Mo-99) produced using IBA's accelerators and beamlines, according to the vendors. Mo-99 is the precursor to Tc-99m.

The expanded partnership builds on a previous contract under which IBA is providing NorthStar with up to eight of its Rhodotron TT 300-HE electron beam accelerators for producing nonuranium-based Mo-99. NorthStar's RadioGenix system will then use the Mo-99 to produce Tc-99m in the U.S.

The first pair of IBA accelerators are expected to arrive from Belgium in early April at NorthStar's expanded accelerator production facility in Beloit, WI.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking